The STEP-1 trial reported approximately 15% average body weight reduction with semaglutide 2.4mg over 68 weeks
Under-eating can contribute to muscle loss, fatigue, and nutritional deficiencies
Real-world Effectiveness : Clinical trial settings may not fully reflect real-world implementation challenges, including adherence, lifestyle support, and healthcare system integration
Gastrointestinal adverse events were reported in 62% of the group taking semaglutide, compared to 42% in the placebo group.[ref] Bigger picture of GLP-1 in the rise of obesity: Several recent studies shed light on how environmental factors may be causing a decrease in GLP-1 levels
A large real-world study published in 2026 in the journal Inflammatory Bowel Diseases found that GLP-1 use in people with UC and Crohns disease was linked to lower rates of steroid use, hospitalization, and intestinal surgery
Subramaniam, S., Joyce, P., Thomas, N